| 临床或病理特征 | ypN0 | non-ypN0 | χ2 | p |
| Ki-67 |
|
| 8.215 | 0.005 |
| Ki-67 < 30% | 27 (28.7%) | 67 (71.3%) |
|
|
| Ki-67 ≥ 30% | 121 (45.7%) | 144 (54.3%) |
|
|
| 肿瘤临床分期 |
|
| 3.304 | 0.192 |
| cT1 | 17 (56.7%) | 13 (43.3%) |
|
|
| cT2 | 68 (39.1%) | 106 (60.9%) |
|
|
| cT3 | 63 (40.6%) | 92 (59.4%) |
|
|
| 腋窝淋巴结临床分期 |
|
| 0.146 | 0.929 |
| cN1 | 106 (41.7%) | 148 (58.3%) |
|
|
| cN2 | 36 (39.6%) | 55 (60.4%) |
|
|
| cN3 | 6 (42.9%) | 8 (57.1%) |
|
|
| 组织学分级 |
|
| 0.76 | 0.684 |
| I | 4 (33.3%) | 8 (66.7%) |
|
|
| II | 123 (42.3%) | 168 (57.7%) |
|
|
| III | 21 (37.5%) | 35 (62.5%) |
|
|
| MRI评估肿瘤化疗反应 |
|
| 61.152 | <0.001 |
| CR | 39 (75.0%) | 13 (25.0%) |
|
|
| PR | 95 (47.0%) | 107 (53.0%) |
|
|
| SD | 14 (13.6%) | 89 (86.4%) |
|
|
| PD | 0 | 2 (100%) |
|
|
| MRI评估腋窝淋巴结化疗反应 |
|
| 34.579 | <0.001 |
| CR | 73 (63.5%) | 42 (36.5%) |
|
|
| non-CR | 75 (30.6%) | 169 (69.3%) |
|
|
| 肿瘤分子亚型 |
|
| 100.641 | <0.001 |
| Luminal | 23 (14.5%) | 136 (85.6%) |
|
|
| Her-2 | 107 (70.4%) | 45 (29.6%) |
|
|
| TNBC | 18 (37.5%) | 30 (62.5%) |
|
|